Atritech Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 27
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $712M
Latest Deal Amount

Atritech General Information

Description

Developer of minimally invasive technologies designed for the prevention of atrial fibrillation related stroke and related diseases. The company's proprietary product WATCHMAN, offers left atrial appendage system, which is designed to prevent harmful sized blood clots formed in the left atrial appendage from entering into blood streams that causes strokes or other complications thus, enabling on improving the quality of life for patients with atrial fibrillation (AF) by providing a permanent alternative to medications that help reduce the risk of AF related stroke.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Acquirer
Boston Scientific
Primary Office
  • 3750 Annapolis Lane
  • Suite 105
  • Plymouth, MN 55447
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Atritech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 19-Jan-2011 $712M 000.00 00000 Completed Generating Revenue
6. Later Stage VC (Series E) 07-Apr-2009 0000 000.00 00000 Completed Generating Revenue
5. Later Stage VC (Series D) 05-Sep-2007 0000 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 08-Mar-2006 0000 000.00 000.00 Completed Generating Revenue
3. Convertible Debt 26-Jun-2005 00.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 11-Sep-2003 $10.2M $17.2M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) $7M $7M 000.00 Completed Generating Revenue
To view Atritech’s complete valuation and funding history, request access »

Atritech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 8,123,560 $0.010000 8% $1.25 $1.25 1x $1.25 8.83%
Series A 5,600,000 $0.010000 8% $1.25 $1.25 1x $1.25 6.09%
To view Atritech’s complete cap table history, request access »

Atritech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Atritech Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Affinity Capital Management Venture Capital Minority 000 0000 000000 0
BioStar Capital Venture Capital Minority 000 0000 000000 0
Cressey & Company PE/Buyout Minority 000 0000 000000 0
Edwards Lifesciences Corporation Minority 000 0000 000000 0
Prism Venture Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »